Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of avacopan in ANCA-associated vasculitis
2023-503184-42-00Phase 4Suspended
- Sponsor
- Amgen
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, double-blind trial of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (3 arms), sponsored by Amgen. Started Sep 2024; status: suspended.
02
Drugs
avacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2023-503184-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503184-42-00.